Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

MLA

Van Cutsem, E., et al. Nintedanib for the Treatment of Patients with Refractory Metastatic Colorectal Cancer (LUME-Colon 1): A Phase III, International, Randomized, Placebo-Controlled Study. Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f41d65dc8d8674d58105961d203252fe&authtype=sso&custid=ns315887.

APA

Van Cutsem, E., Yoshino, T., Lenz, H. J., Lonardi, S., Falcone, A., Limón, M. L., Saunders, M., Sobrero, A., Park, Y. S., Ferreiro, R., Hong, Y. S., Tomasek, J., Taniguchi, H., Ciardiello, F., Stoehr, J., Oum’Hamed, Z., Vlassak, S., Studeny, M., Argiles, G., & Universitat Autònoma de Barcelona. (2018). Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.

Chicago

Van Cutsem, E, T Yoshino, H J Lenz, S Lonardi, A Falcone, M L Limón, M Saunders, et al. 2018. “Nintedanib for the Treatment of Patients with Refractory Metastatic Colorectal Cancer (LUME-Colon 1): A Phase III, International, Randomized, Placebo-Controlled Study,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f41d65dc8d8674d58105961d203252fe&authtype=sso&custid=ns315887.